| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 10800530 | Biochimica et Biophysica Acta (BBA) - General Subjects | 2013 | 8 Pages |
Abstract
A more detailed analysis of the dose and administration schedule employed for (pGlu-Gln)-CCK-8[mPEG] could provide a novel and effective compound to treat obesity-diabetes.
Related Topics
Life Sciences
Biochemistry, Genetics and Molecular Biology
Biochemistry
Authors
Nigel Irwin, Pamela Frizelle, Finbarr P.M. O'Harte, Peter R. Flatt,
![First Page Preview: (pGlu-Gln)-CCK-8[mPEG]: A novel, long-acting, mini-PEGylated cholecystokinin (CCK) agonist that improves metabolic status in dietary-induced diabetes (pGlu-Gln)-CCK-8[mPEG]: A novel, long-acting, mini-PEGylated cholecystokinin (CCK) agonist that improves metabolic status in dietary-induced diabetes](/preview/png/10800530.png)